• ORIC Pharmaceuticals reported new data at ESMO Congress 2026 on enozertinib in first line EGFR atypical NSCLC and on rinzimetostat in metastatic prostate cancer, including safety and response measures that support advancing both assets into late stage trials.
• The twin focus on brain penetrant EGFR inhibition in lung cancer and PRC2 targeting in prostate cancer highlights how ORIC Pharmaceuticals is aiming to convert resistance biology into two potential franchise-scale product opportunities, supported by an extended cash runway.
• The focus now turns to how ORIC Pharmaceuticals’ updated ESMO data for enozertinib might reshape the broader investment narrative around its oncology pipeline.

Spot 21 high quality undiscovered gems that, like ORIC Pharmaceuticals, are trying to turn tight oncology niches and resistance biology into under-the-radar therapeutic franchises.

ORIC Pharmaceuticals Investment Narrative Recap

To own ORIC Pharmaceuticals, you need to believe its two lead assets can convert resistance biology into real oncology franchises before the cash runway into the second half of 2028 starts to tighten. The near term story is about clean execution in Phase 3 scale programs while the business still has no revenue and ongoing losses.

Right now, the key upside swing factor is whether enozertinib and rinzimetostat can sustain their current activity and tolerability profiles as patient numbers grow. The main operational risk is delay, cost inflation or weaker than expected late stage data that could force fresh equity funding on tougher terms and dilute existing holders.

The most relevant update is the new enozertinib dataset in first line EGFR atypical NSCLC and ORIC Pharmaceuticals’ decision to push into the global Phase 3 REDWOOD 1 trial. That move crystallises a clear clinical catalyst path and locks in substantial trial spend over the next few years.

For you as a shareholder, REDWOOD 1 now sits alongside Himalayas 1 as a twin late stage test of ORIC’s thesis that resistance focused drugs can earn share in crowded lung and prostate cancer segments. Execution risk increases with this step up in scope, although current cash of US$388m is guided to cover both programs into 2028.

ORIC Pharmaceuticals’ outlook projects US$24.7 million in revenue and US$4.3 million in earnings by 2029. This projection assumes revenue builds from a zero base and implies an earnings increase of about US$144.7 million from the current earnings level of a US$140.4 million loss.

Uncover why ORIC Pharmaceuticals' fair value indicates a 57% potential upside to its current price, which could narrow quickly.

Exploring Other Perspectives

One bullish twist you might want to stress test is how much weight the most optimistic analysts put on enozertinib after ESMO 2026. Before this update, they were already pencilling in US$41.5 million of revenue and US$7.2 million of earnings potential by 2029 for ORIC Pharmaceuticals. That is far above the US$24.7 million and US$4.3 million embedded in the baseline view. These projections could shift again as opinions adjust. Use the spread between those forecasts as a reminder that smart people can look at the same data and reach very different conclusions, which is exactly why you should explore multiple angles before deciding what this new data means for you.

Explore 3 other ORIC Pharmaceuticals fair value estimates, including one that suggests as much as 230% potential upside from the current price.

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your ORIC Pharmaceuticals research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• See our latest analysis for ORIC Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate ORIC Pharmaceuticals' overall financial health at a glance.

Looking For More Ideas Beyond ORIC Pharmaceuticals?

Once you have a view on ORIC Pharmaceuticals, it can help to compare that thesis with other opportunities using the Simply Wall St Screener so your portfolio is not overly tied to the outcome of one oncology story.

• If you care most about resilient balance sheets and business quality, start with a list of solid balance sheet and fundamentals (25 results) that can help you focus on sturdier foundations.
• If potential value gaps catch your eye, scan through a 27 high quality undervalued stocks that highlights companies where fundamentals and price do not fully line up.
• If capital preservation and smoother rides matter to you, filter for a 30 resilient stocks with low risk scores to see which stocks score better on Simply Wall St's risk checks.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.